| Lurasidone for schizophrenia: what's different? | |
| | |
MedLine Citation:
|
PMID: 22364325 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Lurasidone is one of several antipsychotics approved in the recent past by the US FDA for the treatment of schizophrenia. Several Phase II and III studies have established that lurasidone is more efficacious than placebo. There are no available adequately powered head-to-head comparisons of efficacy of lurasidone with other antipsychotics. However, in contrast to some other antipsychotics, lurasidone is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, or the ECG QT interval. As per the product label, the recommended starting dose is 40 mg/day and the maximum recommended dose is 80 mg/day. Higher doses do not appear to be more efficacious, and may be associated with increases in adverse effects, such as somnolence and akathisia; however, this tolerability issue was not observed in one recently conducted 6-week study when lurasidone was administered at a dose of 160 mg/day. It is recommended that lurasidone be administered once daily with at least 350 calories of food. Additional studies are desirable to directly compare and contrast lurasidone with other antipsychotic agents. |
| | |
Authors:
|
Joshua T Kantrowitz; Leslie Citrome |
Related Documents
:
|
22374205 - How's my dosing? a one-step, math-free guide for comparing your clinic's maintenance im... 22809245 - Clinical development of a once-daily gastroretentive formulation of gabapentin for trea... 22299825 - Optimisation of dmpk by the inhaled route: challenges and approaches. 17267325 - Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase ... 17320805 - Comparison of pleurodesis by erythromycin, talc, doxycycline, and diazepam in a rabbit ... 10815855 - 308-nm excimer laser for the treatment of psoriasis: a dose-response study. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of neurotherapeutics Volume: 12 ISSN: 1744-8360 ISO Abbreviation: Expert Rev Neurother Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-02-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101129944 Medline TA: Expert Rev Neurother Country: England |
Other Details:
|
Languages: eng Pagination: 265-73 Citation Subset: IM |
Affiliation:
|
Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA. jkantrowitz@nki.rfmh.org. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Metal-Organic Chemical Vapor Deposition of Phase Change Ge1Sb2Te4 nanowires.
Next Document: Vigabatrin monotherapy for infantile spasms.